Sleep apnea detection comes to Apple Watch for Australians
Technology
Sleep
World
health CONTACT US
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sky News AU
11 hours ago
- Sky News AU
The Project star Meshel Laurie reveals whopping 60kg weight loss as she pleads for government to add Ozempic to PBS
Meshel Laurie has got candid about her whopping 60kg weight loss as she called for a controversial obesity medication to be added to the Pharmaceutical Benefits Scheme (PBS). The Project panellist, 51, has been open about her extreme physical transformation after undergoing gastric bypass surgery in 2016, which resulted in the TV host looking completely unrecognisable. Meshel appeared on the Kyle and Jackie O show on Tuesday, where she admitted to having recently taken weight loss medication Mounjaro and credited the drug with helping her lower the scale. She called on the Albanese government to add the GLP-1 injectable drug, similar to Ozempic, to the PBS to subsidise the cost and make it more affordable for Australians, describing the effects as "amazing" and "life-changing". "I have to make a plea to the government to add this medication to the PBS, please, because it costs over $600 a month," she said. "For a lot of people, it's prohibitive." "If obesity costs Australia about $12 billion a year, then surely, we can afford to make this medication more affordable." Mounjaro was initially used for treating type 2 diabetes until it gained popularity for its weight loss effects in recent years. The Therapeutic Goods Administration (TGA) in 2024 expanded the drug's usage to encompass obese or overweight Australians with weight-related health issues like high blood pressure, heart disease or sleep apnoea. Speaking about the reported side effects, including stomach pains, Mishel said she hasn't experienced any. She said even if she had, it would be "worth it" to continue achieving a physical transformation while bypassing any "exercise" in the process. "As I said, I did everything else before. So, I lost a bit of weight, I lost about 30kg. "And then about a year ago, I started using Mounjaro. "And that has not only knocked off the next 30-40kgs, but it has absolutely dealt with the problem. Like, I don't think about food anymore." Elsewhere in the wide-ranging interview, Meshel opened up about the personal heartbreak that spurred her to lose weight in the first place. 'My dad died of Type 2 Diabetes (in) 2019,' she said. 'But for the five years before that he lived with the kids and I. 'I was watching (him suffer) in real time, out the kitchen window, because he was in a granny flat. I didn't put him in the driveway; he had a flat.' The media personality was a regular on Ten's The Project from 2014 to 2018, after which she was sacked while on leave for her father's health. Meshel said she was ready to go back to work after 12 weeks, only to be told all the "spots were filled for the next couple of months" 'In fact, I was never notified that I was being let go," she said on Instagram. Meshel subsequently carved out a career as an author and published her bestselling novel, Buddhism for the Unbelievably Busy, in 2017, followed by CSI Told You Lies: Giving Victims a Voice Through Forensics in 2021. In Buddhism for the Unbelievably Busy, Meshel declared she was "embarrassed" about having had surgery to lose weight. "Yes, it's embarrassing to have to go to that length to rein my body in, but I'd rather be embarrassed than unable to walk," she wrote. "In a way, I feel lucky to have had such clear signals from my body that I needed to turn my health burner back on, when I still had time to do something about it."
AU Financial Review
a day ago
- AU Financial Review
Small cap Stealth turns exclusive iPhone case rights into market buzz
Apple's global iPhone 17 rollout will be an earnings bonanza for Stealth Group after it secured exclusive distribution rights for some of the world's largest mobile accessory makers. The ASX‑listed minnow, with a market cap of just $93.3 million, has locked in about $6.5 million in presales for accessories including phone cases and screen protectors – up 50 per cent on the previous iPhone launch – the company said on Monday, while upgrading its near-term revenue outlook.
The Australian
3 days ago
- The Australian
Spike in adverse event reports for ADHD medication Vyvanse
Authorities are investigating a spike in incidents involving one of Australia's most widely used ADHD medications. Adverse event reports linked to medication Vyvanse have spiked massively this year, and the manufacturer says no changes in the chemical production have been made. 'The Therapeutic Goods Administration (TGA) is currently investigating a potential safety signal associated with Vyvanse, including independent testing of the medicine through the TGA Laboratories,' a spokesperson told NewsWire. 'The investigation is the result of a recent increase in adverse event notifications relating to concerns about the quality, safety, and reduced effectiveness of the drug.' The TGA issued an alert about a typo on the Vyvanse label earlier this year. Picture: TGA 'There are no compliance signals currently under investigation for the facilities used in the manufacture of this product.' A 'signal' is detection of a pattern which requires further investigation. While not formally a pattern in the TGA's eyes, reports of adverse events such as anxiety, ineffectiveness and insomnia have increased massively this year. There have also been 88 reports of issues with the medicines label, which was flagged by the TGA earlier this year for minor typos; however, one of the typos added an extra 'S' to the word capsule; 'Each capsules contains 60mg lisdexamfetamine dimesilate'. The TGA maintains the Database of Adverse Event Notifications, where people report issues with medications. There have been 320 adverse events linked to Vyvanse in the first half of this year, compared to nine reports in the second half of 2024. Inclusion in the database does not confirm the incident is caused by the medication. Reports of ineffective Vyvanse have hit 150 so far this year, along with 88 reports of anxiety, and 73 reports that the therapeutic response has decreased. Last year, 1.8m Vyvanse prescriptions were written in Australia, excluding Department of Veterans' Affairs patients, over-the-counter drugs, private prescriptions and public inpatient prescriptions. Picture: NewsWire / Martin Ollman Prescriptions of Vyvanse have been steadily increasing for the past few years. More than 958,000 scripts were written by public system health workers in 2022, rising to 1.4 million in 2023, and then 1.8m last year, government data shows. In a statement, supplier Takeda Pharmaceuticals Australia said a change of manufacturing facility in 2024 did not alter the chemical composition of the medicine. 'There have been no changes to the formulation,' a Takeda spokesperson told the ABC. Vyvanse was produced with strict quality controls, in line with Australia's Therapeutics Goods Act, the spokesperson said. The labelling typo did not affect the quality of the medication, they said. Blair Jackson Reporter Blair's journalism career has taken him from Perth, to New Zealand, Queensland and now Melbourne. Blair Jackson
